The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Cancer Res. 2011 Sep 1;71(17):5850-8. doi: 10.1158/0008-5472.CAN-11-1014. Epub 2011 Jul 22.
The Bcl-2 family encompasses a diverse set of apoptotic regulators that are dynamically activated in response to various cell-intrinsic and -extrinsic stimuli. An extensive variety of cell culture experiments have identified effects of growth factors, cytokines, and drugs on Bcl-2 family functions, but in vivo studies have tended to focus on the role of one or two particular members in development and organ homeostasis. Thus, the ability of physiologically relevant contexts to modulate canonical dependencies that are likely to be more complex has yet to be investigated systematically. In this study, we report findings derived from a pool-based shRNA assay that systematically and comprehensively interrogated the functional dependence of leukemia and lymphoma cells upon various Bcl-2 family members across many diverse in vitro and in vivo settings. This approach permitted us to report the first in vivo loss of function screen for modifiers of the response to a front-line chemotherapeutic agent. Notably, our results reveal an unexpected role for the extrinsic death pathway as a tissue-specific modifier of therapeutic response. In particular, our findings show that particular tissue sites of tumor dissemination play critical roles in demarcating the nature and extent of cancer cell vulnerabilities and mechanisms of chemoresistance.
Bcl-2 家族包含了一组多样化的凋亡调节剂,它们能够对各种细胞内和细胞外的刺激做出动态响应。大量的细胞培养实验已经确定了生长因子、细胞因子和药物对 Bcl-2 家族功能的影响,但体内研究往往集中于一两个特定成员在发育和器官稳态中的作用。因此,生理相关环境调节可能更复杂的典型依赖性的能力尚未得到系统研究。在这项研究中,我们报告了基于池的 shRNA 测定的结果,该测定系统而全面地研究了在许多不同的体外和体内环境中各种 Bcl-2 家族成员对白血病和淋巴瘤细胞的功能依赖性。这种方法使我们能够报告首例针对一线化疗药物反应的功能丧失筛选调节剂。值得注意的是,我们的结果揭示了外在死亡途径作为治疗反应的组织特异性调节剂的意外作用。具体来说,我们的发现表明肿瘤播散的特定组织部位在划定癌细胞脆弱性的性质和程度以及化疗耐药的机制方面起着关键作用。